HRS-7085 tablets for adults with moderate to severe ulcerative colitis

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a randomized, double-blind, placebo-controlled Phase 2 trial with screening, a treatment period, and follow-up to measure efficacy, safety, and pharmacokinetics of oral HRS-7085. Participants must have moderately to severely active ulcerative colitis confirmed by a 9-point modified Mayo score and a central endoscopic read. The trial compares HRS-7085 to placebo and collects clinical scores, endoscopy findings, safety labs, and drug concentration data. Eligible patients have prior inadequate response or intolerance to conventional or biologic/JAK treatments and will be monitored for symptom improvement and adverse events.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Male and female subject age ≥ 18，≤75.
2. the body mass index (BMI= weight (kg)/height (2 m ²)) of the subjects is ≥ 18 kg/m ².
3. Subject has active Ulcerative Colitis with a 9-point modified Mayo score of 4-9 at baseline, with an endoscopic subscore of ≥ 2 (confirmed by central read), and rectal bleeding subscore of ≥1.
4. Subject has at least a 90-days history of Ulcerative Colitis diagnosis at baseline.
5. Subject is deemed by the physician as having inadequate response, loss of response or intolerance to at least one conventional treatment (oral 5-ASA, immunosuppressants or corticosteroids), or anti-TNF therapy (e.g., infliximab, adalimumab) or other biological, or JAK inhibitors treatment.
6. Subject is capable of providing a signed and dated informed consent form indicating the subject has been informed of all pertinent aspects of the study.
7. All women of childbearing potential and their male partners must commit to using a highly effective contraception to 3 months after last dose of study medication.

Exclusion Criteria:

1. Subject has a diagnosis of indeterminate colitis, or clinical findings suggestive of Crohn's Disease.
2. Subject with Ulcerative Colitis, which is confined to a proctitis (distal 15 cm or less).
3. Treatment naïve subject diagnosed with Ulcerative Colitis.
4. Subject is displaying clinical signs of ischemic colitis, fulminant colitis or toxic megacolon.
5. Subject had previous surgery as a treatment for Ulcerative Colitis or likely to require surgery during the study period.
6. Screening endoscopic examination revealed that the subjects had a history of gastrointestinal dysplasia (atypical hyperplasia)/cancer or dysplasia (atypical hyperplasia)/cancer. Except for completely resected low-grade dysplasia.
7. Subject has evidence of pathogenic bowel infection. Subjects had Clostridium difficile or other intestinal infection within 30 days of screening endoscopy or test positive at screening for C. difficile toxin or other intestinal pathogens.
8. Subject currently has or had:

   8.1 A clinically significant infection within 1 month of baseline. 8.2 A history of more than one episode of herpes zoster, or disseminated zoster (single episode).

   8.3 Any infection otherwise judged by the investigator to have the potential for exacerbation by participation in the study.

   8.4Any infection requiring antimicrobial therapy within 2 weeks of screening.
9. Subject is receiving any of the following therapies:

9.1 Cyclosporine, mycophenolate, tacrolimus、JAK inhibitors within 4 weeks prior to baseline.

9.2 Interferon therapy within 8 weeks prior to baseline. 9.3 Intravenous corticosteroids or rectally administered formulation of corticosteroids or 5-ASA within 2 weeks prior to baseline.

Where it's running

• West China Hospital of Sichuan University
  Chengdu, Sichuan, China Recruiting

Study contacts

• Study coordinator: Tingyu Dong
• Email: tingyu.dong@hengrui.com
• Phone: 0518-82342973

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• HRS-1780 for people with uncontrolled or resistant high blood pressure

  This trial tests whether HRS-1780 can safely help adults with uncontrolled or resistant hypertension.

  Recruiting at 2 sites Phase 2/3 Shandong Suncadia Medicine Co., Ltd. · Chongqing, Chongqing Municipality and 1 other locations · NCT07708441

• HRS-2129 for Acute Gouty Arthritis: Quick Safety and Dosing Check

  A Phase 2 trial tests whether HRS-2129 tablets, at different doses, are safe and helpful for people with acute gouty arthritis.

  Recruiting at 2 sites Phase 2 Shandong Suncadia Medicine Co., Ltd. · Guangzhou, Guangdong and 1 other locations · NCT07706777

• Safety test of HRS-7156 in healthy adults

  This study tests whether HRS-7156 is safe and tolerated in healthy adults aged 18–55.

  Recruiting Phase 1 Shandong Suncadia Medicine Co., Ltd. · Shanghai, Shanghai Municipality · NCT07601087

• KRAS G12C pancreatic cancer: a single-arm study of HRS-7058

  This study tests whether the KRAS G12C inhibitor HRS-7058 can help adults with advanced pancreatic cancer who have already tried other treatments.

  Recruiting at 2 sites Phase 2 Shandong Suncadia Medicine Co., Ltd. · Nanjing, Jiangsu and 1 other locations · NCT07589569

• Blood pressure medicine HRS-7535 tested in adults with hypertension and overweight/obesity

  This study tests whether HRS-7535 lowers blood pressure better than placebo in adults with hypertension who are overweight or obese.

  Recruiting at 2 sites Phase 3 Shandong Suncadia Medicine Co., Ltd. · Beijing, Beijing Municipality and 1 other locations · NCT07528027

• HRS-1780 to slow kidney function decline in people with chronic kidney disease

  We will test whether daily HRS-1780 tablets can slow kidney function decline compared with placebo in adults with chronic kidney disease who are on standard treatment.

  Recruiting Phase 3 Shandong Suncadia Medicine Co., Ltd. · Nanjing, Jiangsu · NCT07419828

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.